Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 168,184,992
  • Shares Outstanding, K 2,735,160
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.80
  • Price/Sales 4.25
  • Price/Cash Flow 10.67
  • Price/Book 4.26

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.16 +0.54%
on 08/18/17
64.55 -4.74%
on 07/27/17
-0.92 (-1.47%)
since 07/18/17
3-Month
61.16 +0.54%
on 08/18/17
66.40 -7.39%
on 06/26/17
-2.40 (-3.76%)
since 05/18/17
52-Week
58.29 +5.49%
on 11/03/16
66.80 -7.95%
on 03/01/17
-2.14 (-3.36%)
since 08/18/16

Most Recent Stories

More News
AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada

AbbVie (ABBV) announces Mavyret's sanction in Canada for treatment of HCV across all major genotypes. This gain serves a big boost to the company's product portfolio.

ENTA : 37.96 (-3.92%)
MRK : 61.49 (-0.57%)
ABBV : 69.96 (+0.16%)
GILD : 72.11 (-0.32%)
Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada

Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.

MRK : 61.49 (-0.57%)
ABBV : 69.96 (+0.16%)
GILD : 72.11 (-0.32%)
BMY : 56.42 (-0.62%)
Merck & Co (MRK) Crosses Pivot Point Support at $61.43

Merck & Co (NYSE:MRK) has opened bearishly below the pivot of $62.22 today and has reached the first level of support at $61.43. Analysts will be watching for a cross of the next downside pivot targets...

MRK : 61.49 (-0.57%)
AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion

AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.

AZN : 29.12 (+0.14%)
MRK : 61.49 (-0.57%)
CLVS : 71.96 (+2.99%)
TSRO : 113.86 (+4.41%)
Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo

Key highlights this week in the pharmaceutical sector include the launch of a drug pricing probe, a resignation from the President's manufacturing council and data on Bristol-Myers' (BMY) Opdivo.

MYL : 30.72 (+0.52%)
AZN : 29.12 (+0.14%)
MRK : 61.49 (-0.57%)
NVS : 82.76 (-0.50%)
PFE : 32.67 (-0.85%)
GSK : 38.75 (-0.77%)
BMY : 56.42 (-0.62%)
LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer

--LYNPARZA Tablets Also Indicated in BRCA-Mutated Ovarian Cancer Beyond the Third-Line Setting

MRK : 61.49 (-0.57%)
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?

Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.

AZN : 29.12 (+0.14%)
MRK : 61.49 (-0.57%)
NVS : 82.76 (-0.50%)
PFE : 32.67 (-0.85%)
Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214

Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.

AZN : 29.12 (+0.14%)
MRK : 61.49 (-0.57%)
RHHBY : 31.2300 (-0.98%)
BMY : 56.42 (-0.62%)
Business leaders quit Trump panel; he hits back hard

WASHINGTON (AP) — President Donald Trump on Tuesday ripped into business leaders who resigned from his White House jobs panel — the latest sign that corporate America's romance with Trump is faltering...

CPB : 53.69 (-0.50%)
MRK : 61.49 (-0.57%)
JNJ : 132.63 (-0.31%)
A Complete List of CEOs Who've Left Trump's Manufacturing Council, So Far

President Donald Trump's power to polarize continued after the weekend's tragic events in Charlottesville, Va.--and his subsequent remarks--caused the president to become further isolated from some members...

TSLA : 347.46 (-1.27%)
UAA : 17.12 (-3.87%)
TWTR : 15.99 (+0.76%)
F : 10.56 (-0.75%)
INTC : 35.01 (-0.45%)
MRK : 61.49 (-0.57%)
DOW : 63.40 (+0.35%)
DKS : 26.99 (-2.70%)
GE : 24.55 (-0.81%)
BA : 235.77 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 62.14
1st Resistance Point 61.81
Last Price 61.49
1st Support Level 61.16
2nd Support Level 60.84

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.